Concepts (269)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vascular Stiffness | 9 | 2023 | 76 | 4.100 |
Why?
|
| Hypertension | 17 | 2024 | 1349 | 4.020 |
Why?
|
| Blood Pressure | 19 | 2024 | 1340 | 3.590 |
Why?
|
| Dyslipidemias | 14 | 2026 | 249 | 2.990 |
Why?
|
| Cardiovascular Diseases | 14 | 2025 | 2094 | 1.820 |
Why?
|
| Environmental Exposure | 4 | 2026 | 292 | 1.740 |
Why?
|
| Atherosclerosis | 5 | 2026 | 947 | 1.610 |
Why?
|
| American Heart Association | 11 | 2026 | 339 | 1.450 |
Why?
|
| Adipokines | 3 | 2017 | 118 | 1.440 |
Why?
|
| Obesity | 10 | 2026 | 2394 | 1.430 |
Why?
|
| Hypolipidemic Agents | 4 | 2026 | 195 | 1.410 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 5 | 2022 | 51 | 1.330 |
Why?
|
| Pulse Wave Analysis | 7 | 2023 | 48 | 1.280 |
Why?
|
| Aortic Coarctation | 2 | 2023 | 98 | 1.270 |
Why?
|
| Mass Screening | 5 | 2026 | 812 | 1.220 |
Why?
|
| Hypertrophy, Left Ventricular | 5 | 2025 | 109 | 1.200 |
Why?
|
| Echocardiography | 5 | 2025 | 1130 | 1.110 |
Why?
|
| Lipids | 4 | 2020 | 559 | 1.070 |
Why?
|
| Adolescent | 42 | 2026 | 20802 | 1.060 |
Why?
|
| Pediatric Obesity | 4 | 2025 | 413 | 1.010 |
Why?
|
| Rheumatic Heart Disease | 2 | 2018 | 39 | 0.970 |
Why?
|
| Risk Factors | 25 | 2026 | 10953 | 0.930 |
Why?
|
| Insulin Resistance | 4 | 2025 | 685 | 0.890 |
Why?
|
| Child | 39 | 2026 | 26181 | 0.870 |
Why?
|
| Hyperglycemia | 2 | 2025 | 233 | 0.850 |
Why?
|
| Vulnerable Populations | 1 | 2026 | 148 | 0.830 |
Why?
|
| Body Mass Index | 7 | 2021 | 1685 | 0.790 |
Why?
|
| Hyperinsulinism | 1 | 2023 | 57 | 0.760 |
Why?
|
| Ductus Arteriosus | 1 | 2023 | 61 | 0.750 |
Why?
|
| Pediatrics | 5 | 2021 | 1242 | 0.750 |
Why?
|
| Life Style | 3 | 2021 | 446 | 0.730 |
Why?
|
| Hemodynamics | 4 | 2017 | 810 | 0.730 |
Why?
|
| Aorta | 3 | 2023 | 522 | 0.710 |
Why?
|
| Humans | 69 | 2026 | 130154 | 0.690 |
Why?
|
| Blood Pressure Determination | 2 | 2024 | 118 | 0.690 |
Why?
|
| Referral and Consultation | 2 | 2016 | 551 | 0.680 |
Why?
|
| Lipid Metabolism Disorders | 1 | 2021 | 4 | 0.680 |
Why?
|
| Male | 48 | 2026 | 64397 | 0.670 |
Why?
|
| Metabolic Syndrome | 4 | 2021 | 365 | 0.650 |
Why?
|
| Young Adult | 15 | 2026 | 9987 | 0.610 |
Why?
|
| Female | 46 | 2026 | 70285 | 0.610 |
Why?
|
| Nutrition Surveys | 2 | 2018 | 328 | 0.580 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 7 | 2026 | 744 | 0.570 |
Why?
|
| Lead | 1 | 2018 | 25 | 0.570 |
Why?
|
| Manometry | 1 | 2017 | 75 | 0.530 |
Why?
|
| Cross-Sectional Studies | 9 | 2019 | 3781 | 0.530 |
Why?
|
| Longitudinal Studies | 7 | 2025 | 1485 | 0.520 |
Why?
|
| Triglycerides | 4 | 2026 | 601 | 0.520 |
Why?
|
| Child of Impaired Parents | 1 | 2017 | 20 | 0.520 |
Why?
|
| Biomarkers | 11 | 2026 | 3360 | 0.510 |
Why?
|
| United States | 18 | 2026 | 11885 | 0.500 |
Why?
|
| Healthy Lifestyle | 1 | 2016 | 33 | 0.490 |
Why?
|
| Body Weight | 1 | 2020 | 985 | 0.490 |
Why?
|
| Aorta, Thoracic | 1 | 2021 | 527 | 0.480 |
Why?
|
| Population Surveillance | 1 | 2018 | 393 | 0.470 |
Why?
|
| Heart Defects, Congenital | 2 | 2023 | 1880 | 0.470 |
Why?
|
| Office Visits | 1 | 2016 | 79 | 0.460 |
Why?
|
| Models, Econometric | 1 | 2015 | 8 | 0.450 |
Why?
|
| Quinolines | 2 | 2026 | 115 | 0.440 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2014 | 10 | 0.440 |
Why?
|
| Markov Chains | 1 | 2015 | 101 | 0.430 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2016 | 161 | 0.430 |
Why?
|
| Heart Rate | 1 | 2017 | 573 | 0.420 |
Why?
|
| Cholesterol Ester Transfer Proteins | 2 | 2011 | 39 | 0.410 |
Why?
|
| Incidence | 7 | 2021 | 3314 | 0.410 |
Why?
|
| Environmental Pollutants | 2 | 2025 | 78 | 0.410 |
Why?
|
| Drug Prescriptions | 1 | 2015 | 229 | 0.390 |
Why?
|
| Primary Prevention | 1 | 2014 | 182 | 0.390 |
Why?
|
| Drug Monitoring | 1 | 2016 | 287 | 0.380 |
Why?
|
| Accessory Atrioventricular Bundle | 1 | 2012 | 9 | 0.380 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2013 | 47 | 0.380 |
Why?
|
| Practice Guidelines as Topic | 4 | 2021 | 1282 | 0.380 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2012 | 17 | 0.370 |
Why?
|
| Multivariate Analysis | 6 | 2017 | 1374 | 0.370 |
Why?
|
| Electronic Health Records | 2 | 2017 | 831 | 0.370 |
Why?
|
| Diabetes Mellitus | 2 | 2017 | 887 | 0.360 |
Why?
|
| Carotid Artery Diseases | 1 | 2013 | 130 | 0.360 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2012 | 47 | 0.360 |
Why?
|
| Ventricular Fibrillation | 1 | 2012 | 51 | 0.360 |
Why?
|
| Adult | 17 | 2023 | 31042 | 0.340 |
Why?
|
| Antihypertensive Agents | 3 | 2024 | 413 | 0.330 |
Why?
|
| Prevalence | 7 | 2018 | 2685 | 0.330 |
Why?
|
| Health Policy | 1 | 2013 | 224 | 0.320 |
Why?
|
| Sex Factors | 4 | 2020 | 1337 | 0.320 |
Why?
|
| Risk Reduction Behavior | 2 | 2026 | 142 | 0.310 |
Why?
|
| Tachycardia, Ventricular | 1 | 2012 | 258 | 0.300 |
Why?
|
| Catheter Ablation | 1 | 2012 | 321 | 0.290 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2009 | 73 | 0.290 |
Why?
|
| Cardiology | 2 | 2024 | 513 | 0.280 |
Why?
|
| Heart Diseases | 1 | 2012 | 500 | 0.270 |
Why?
|
| Retinol-Binding Proteins, Plasma | 2 | 2017 | 16 | 0.260 |
Why?
|
| alpha-2-HS-Glycoprotein | 2 | 2017 | 8 | 0.260 |
Why?
|
| Arterial Pressure | 2 | 2019 | 130 | 0.260 |
Why?
|
| Myocardium | 2 | 2012 | 858 | 0.260 |
Why?
|
| Receptors, Leptin | 2 | 2017 | 40 | 0.260 |
Why?
|
| Fatty Acid-Binding Proteins | 2 | 2017 | 37 | 0.260 |
Why?
|
| Prospective Studies | 8 | 2019 | 6403 | 0.250 |
Why?
|
| Cholesterol, HDL | 3 | 2020 | 383 | 0.250 |
Why?
|
| Cohort Studies | 6 | 2024 | 5042 | 0.250 |
Why?
|
| Adiponectin | 2 | 2017 | 122 | 0.250 |
Why?
|
| Chi-Square Distribution | 3 | 2017 | 563 | 0.250 |
Why?
|
| Carotid Intima-Media Thickness | 2 | 2023 | 77 | 0.230 |
Why?
|
| Leptin | 2 | 2017 | 217 | 0.230 |
Why?
|
| Overweight | 2 | 2026 | 379 | 0.230 |
Why?
|
| Pulmonary Artery | 1 | 2009 | 437 | 0.230 |
Why?
|
| Diet | 2 | 2023 | 1097 | 0.230 |
Why?
|
| Periodontal Diseases | 1 | 2025 | 31 | 0.230 |
Why?
|
| Cadmium | 1 | 2025 | 33 | 0.230 |
Why?
|
| Age Factors | 7 | 2026 | 2823 | 0.230 |
Why?
|
| Indians, North American | 1 | 2025 | 71 | 0.220 |
Why?
|
| Heart Ventricles | 2 | 2009 | 758 | 0.220 |
Why?
|
| Retrospective Studies | 7 | 2018 | 17554 | 0.220 |
Why?
|
| Follow-Up Studies | 4 | 2018 | 5161 | 0.210 |
Why?
|
| Hypertriglyceridemia | 1 | 2026 | 117 | 0.210 |
Why?
|
| Child, Preschool | 7 | 2024 | 15009 | 0.210 |
Why?
|
| Odds Ratio | 2 | 2017 | 1208 | 0.200 |
Why?
|
| Facial Pain | 1 | 2003 | 9 | 0.200 |
Why?
|
| Facial Paralysis | 1 | 2003 | 36 | 0.200 |
Why?
|
| Middle Aged | 11 | 2017 | 28331 | 0.190 |
Why?
|
| Insulin | 2 | 2023 | 1143 | 0.190 |
Why?
|
| Risk Assessment | 5 | 2023 | 3680 | 0.190 |
Why?
|
| Predictive Value of Tests | 3 | 2026 | 2289 | 0.190 |
Why?
|
| Massachusetts | 3 | 2019 | 116 | 0.190 |
Why?
|
| Migraine Disorders | 1 | 2003 | 59 | 0.180 |
Why?
|
| Amlodipine | 1 | 2021 | 21 | 0.180 |
Why?
|
| Logistic Models | 2 | 2017 | 1793 | 0.180 |
Why?
|
| Regression Analysis | 2 | 2020 | 759 | 0.180 |
Why?
|
| Boston | 4 | 2017 | 117 | 0.180 |
Why?
|
| Masked Hypertension | 1 | 2021 | 2 | 0.180 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2024 | 206 | 0.180 |
Why?
|
| Cost-Benefit Analysis | 2 | 2015 | 547 | 0.180 |
Why?
|
| Longevity | 1 | 2023 | 175 | 0.180 |
Why?
|
| White Coat Hypertension | 1 | 2021 | 10 | 0.180 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2009 | 747 | 0.170 |
Why?
|
| Receptor, TIE-2 | 2 | 2012 | 13 | 0.170 |
Why?
|
| Angiopoietin-2 | 2 | 2012 | 12 | 0.170 |
Why?
|
| Databases, Factual | 2 | 2016 | 1230 | 0.160 |
Why?
|
| Prognosis | 3 | 2019 | 4848 | 0.160 |
Why?
|
| Blood Glucose | 3 | 2025 | 1108 | 0.150 |
Why?
|
| Cardiovascular System | 1 | 2020 | 96 | 0.150 |
Why?
|
| Reference Values | 1 | 2020 | 674 | 0.150 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2019 | 37 | 0.150 |
Why?
|
| Brazil | 1 | 2018 | 116 | 0.140 |
Why?
|
| Alanine Transaminase | 1 | 2019 | 154 | 0.140 |
Why?
|
| Glucose | 1 | 2023 | 851 | 0.140 |
Why?
|
| Healthy Volunteers | 1 | 2018 | 152 | 0.130 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2021 | 239 | 0.130 |
Why?
|
| Coronary Disease | 3 | 2011 | 627 | 0.130 |
Why?
|
| Heredity | 1 | 2017 | 15 | 0.130 |
Why?
|
| Health Behavior | 2 | 2020 | 387 | 0.130 |
Why?
|
| Pulse | 1 | 2017 | 28 | 0.130 |
Why?
|
| Electric Impedance | 1 | 2017 | 71 | 0.130 |
Why?
|
| Creatine Kinase | 1 | 2017 | 61 | 0.130 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2019 | 150 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2017 | 1448 | 0.120 |
Why?
|
| Cholesterol, LDL | 2 | 2019 | 605 | 0.120 |
Why?
|
| Recurrence | 2 | 2015 | 1476 | 0.120 |
Why?
|
| Endothelium, Vascular | 1 | 2019 | 467 | 0.120 |
Why?
|
| Muscular Diseases | 1 | 2017 | 119 | 0.120 |
Why?
|
| Benchmarking | 1 | 2016 | 136 | 0.120 |
Why?
|
| Area Under Curve | 1 | 2016 | 303 | 0.110 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2016 | 93 | 0.110 |
Why?
|
| Insurance Claim Review | 1 | 2015 | 26 | 0.110 |
Why?
|
| Northern Territory | 1 | 2015 | 2 | 0.110 |
Why?
|
| Penicillin G Benzathine | 1 | 2015 | 20 | 0.110 |
Why?
|
| Insurance, Health | 1 | 2016 | 142 | 0.110 |
Why?
|
| Rheumatic Fever | 1 | 2015 | 20 | 0.110 |
Why?
|
| Treatment Outcome | 3 | 2026 | 12843 | 0.110 |
Why?
|
| Exercise | 1 | 2021 | 866 | 0.110 |
Why?
|
| Disease Progression | 1 | 2021 | 2193 | 0.110 |
Why?
|
| Demography | 1 | 2015 | 237 | 0.110 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2015 | 127 | 0.110 |
Why?
|
| Alcohol Drinking | 1 | 2017 | 338 | 0.110 |
Why?
|
| ROC Curve | 1 | 2016 | 609 | 0.100 |
Why?
|
| Patient Identification Systems | 1 | 2013 | 3 | 0.100 |
Why?
|
| Vascular Remodeling | 1 | 2014 | 46 | 0.100 |
Why?
|
| Drug Recalls | 1 | 2013 | 3 | 0.100 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2015 | 118 | 0.100 |
Why?
|
| Drug Contamination | 1 | 2013 | 35 | 0.100 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2015 | 120 | 0.100 |
Why?
|
| Pedigree | 1 | 2017 | 1672 | 0.100 |
Why?
|
| Heptanoic Acids | 1 | 2013 | 79 | 0.100 |
Why?
|
| Health Promotion | 1 | 2016 | 413 | 0.090 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2012 | 23 | 0.090 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2012 | 20 | 0.090 |
Why?
|
| Electrophysiology | 1 | 2012 | 243 | 0.090 |
Why?
|
| Blood Flow Velocity | 2 | 2012 | 416 | 0.090 |
Why?
|
| Pyrroles | 1 | 2013 | 189 | 0.090 |
Why?
|
| Double-Blind Method | 2 | 2026 | 1618 | 0.090 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2012 | 43 | 0.090 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2012 | 86 | 0.090 |
Why?
|
| Coronary Artery Disease | 1 | 2019 | 889 | 0.090 |
Why?
|
| Heart Valve Prosthesis | 1 | 2015 | 301 | 0.090 |
Why?
|
| Ventricular Remodeling | 2 | 2025 | 154 | 0.090 |
Why?
|
| Ambulatory Care | 1 | 2015 | 401 | 0.090 |
Why?
|
| Clinical Protocols | 1 | 2013 | 229 | 0.090 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2012 | 134 | 0.090 |
Why?
|
| Aged | 4 | 2017 | 20833 | 0.080 |
Why?
|
| Inflammation | 1 | 2018 | 1481 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 783 | 0.080 |
Why?
|
| Fibrosis | 1 | 2012 | 419 | 0.080 |
Why?
|
| Linear Models | 1 | 2012 | 684 | 0.080 |
Why?
|
| Genotype | 1 | 2016 | 2588 | 0.080 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2012 | 323 | 0.080 |
Why?
|
| Truncus Arteriosus | 1 | 2009 | 13 | 0.080 |
Why?
|
| Phenotype | 1 | 2019 | 4464 | 0.070 |
Why?
|
| Aging | 2 | 2010 | 1236 | 0.070 |
Why?
|
| Ultrasonography | 1 | 2013 | 943 | 0.070 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2009 | 133 | 0.070 |
Why?
|
| Case-Control Studies | 1 | 2015 | 3350 | 0.070 |
Why?
|
| Time Factors | 2 | 2015 | 6178 | 0.070 |
Why?
|
| Tetralogy of Fallot | 1 | 2009 | 171 | 0.070 |
Why?
|
| Residence Characteristics | 1 | 2009 | 293 | 0.060 |
Why?
|
| Heart Atria | 1 | 2010 | 339 | 0.060 |
Why?
|
| Prosthesis Design | 1 | 2009 | 623 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 3407 | 0.060 |
Why?
|
| Reoperation | 1 | 2009 | 813 | 0.060 |
Why?
|
| HIV Infections | 1 | 2018 | 2040 | 0.060 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2009 | 474 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2025 | 296 | 0.050 |
Why?
|
| Myocardial Infarction | 2 | 2002 | 996 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 2577 | 0.050 |
Why?
|
| Canada | 1 | 2023 | 325 | 0.050 |
Why?
|
| Nutritional Status | 1 | 2023 | 298 | 0.040 |
Why?
|
| Latin America | 1 | 2021 | 108 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2025 | 1262 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 1392 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2023 | 406 | 0.040 |
Why?
|
| Private Sector | 1 | 2019 | 26 | 0.040 |
Why?
|
| Myocardial Reperfusion | 1 | 1999 | 53 | 0.040 |
Why?
|
| Financing, Government | 1 | 2019 | 33 | 0.040 |
Why?
|
| Liver Function Tests | 1 | 2019 | 97 | 0.040 |
Why?
|
| Serum | 1 | 2018 | 41 | 0.030 |
Why?
|
| Protein Precursors | 1 | 2018 | 138 | 0.030 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2021 | 482 | 0.030 |
Why?
|
| Troponin T | 1 | 2018 | 255 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 2079 | 0.030 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2018 | 325 | 0.030 |
Why?
|
| Propensity Score | 1 | 2017 | 273 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2018 | 448 | 0.030 |
Why?
|
| Critical Care | 1 | 2021 | 686 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2002 | 4693 | 0.030 |
Why?
|
| Smoking Cessation | 1 | 2016 | 189 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 723 | 0.030 |
Why?
|
| Infant | 2 | 2021 | 13276 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2016 | 293 | 0.030 |
Why?
|
| Health Status | 1 | 2016 | 371 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 4032 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 902 | 0.020 |
Why?
|
| Cytokines | 1 | 2018 | 1342 | 0.020 |
Why?
|
| Comorbidity | 1 | 2016 | 1583 | 0.020 |
Why?
|
| Circadian Rhythm | 1 | 2014 | 314 | 0.020 |
Why?
|
| Survival Rate | 2 | 2009 | 2112 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2002 | 4646 | 0.020 |
Why?
|
| Smoking | 1 | 2016 | 927 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 3025 | 0.020 |
Why?
|
| Organ Size | 1 | 2010 | 408 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 2010 | 461 | 0.020 |
Why?
|
| Heart Failure | 1 | 2002 | 2322 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 1070 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2021 | 8551 | 0.020 |
Why?
|
| Animals | 3 | 2016 | 33698 | 0.010 |
Why?
|
| Atrial Fibrillation | 1 | 2010 | 734 | 0.010 |
Why?
|
| Captopril | 1 | 2002 | 23 | 0.010 |
Why?
|
| Heart Septum | 1 | 2002 | 44 | 0.010 |
Why?
|
| Ligation | 1 | 2002 | 133 | 0.010 |
Why?
|
| Cardiomegaly | 1 | 2002 | 118 | 0.010 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2002 | 214 | 0.010 |
Why?
|
| Mice | 2 | 2002 | 18172 | 0.010 |
Why?
|